A Phase 3 interventional study of Vortioxetine and Escitalopram in Treatment Outcome, sponsored by Takeda. Completed at 62 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-10-09.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Sexual Dysfunction, Physiological with a site in United States — 16 open to participants now, 17 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.
Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 9th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2011, is one of 16 in phase 3, and was the 46th registered.
385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.
Browse Sexual Dysfunction, Physiological studies →16 of the 127 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–45 · Women only
Stanford University · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Sexual Dysfunction, Physiological studies recruiting now, 23 (50%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 16 · Phase 4 13
First in 1998; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 447 is above the median of 72 across 263 interventional studies indexed under Sexual Dysfunction, Physiological.
Median enrollment 60 across the 107 interventional studies, 98 across the 20 observational. Of the 93 that completed or were terminated, 37 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 127 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 1 study filed under Sexual Dysfunction, Physiological — fewer than ten, so there is no comparison to draw.
3 of the studies in Sexual Dysfunction, Physiological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768777University of Alabama at BirminghamBehavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | 2026-12-01 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
The drug being tested in this study is called Lu AA21004. Lu AA21004 is being tested to treat people who have major depressive disorder (MDD). This study will look at sexual function in people who take Lu AA21004.
The study will enroll approximately 440 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one tablet at the same time each day throughout the study. All participants will be asked to answer questionnaires at each study visit.
This multi-centre trial will be conducted in the United States and Canada. The overall time to participate in this study is 14 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 21 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
Drug: Vortioxetine · Drug: Placebo
Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
Drug: Escitalopram
Vortioxetine tablets
Also known as: Lu AA21004
Escitalopram tablets
Also known as: Lexapro
Vortioxetine Placebo-matching capsules
Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.
Time frame: Baseline, Week 8
Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.
Time frame: Baseline and Weeks 1, 2, 4 and 6
Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of \>41 for women and \>47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of ≤41 for women and ≤47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8
Participants took part in the study at 57 sites in the US and 9 sites in Canada from 16 June 12011 to 9 December 2013.
| Milestone | Vortioxetine | Escitalopram |
|---|---|---|
| Started | 225 | 222 |
| Completed | 169 | 179 |
| Not completed | 56 | 43 |
| Withdrew: Pretreatment event or adverse event | 20 | 14 |
| Withdrew: Lack of efficacy | 6 | 0 |
| Withdrew: Non-compliance with investigational drug | 1 | 0 |
| Withdrew: Protocol deviations | 4 | 8 |
| Withdrew: Withdrawal of consent | 9 | 7 |
| Withdrew: Lost to follow-up | 12 | 13 |
| Withdrew: Other | 4 | 1 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.
| scores on a scale | Vortioxetine | Escitalopram |
|---|---|---|
| Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 | 8.8 ± 0.64 | 6.6 ± 0.64 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.
| scores on a scale | Vortioxetine | Escitalopram |
|---|---|---|
| Week 1 (n=213, 206) | 2.5 ± 0.39 | 2.2 ± 0.40 |
| Week 2 (n=203, 200) | 4.9 ± 0.46 | 3.7 ± 0.47 |
| Week 4 (n=187, 188) | 7.0 ± 0.55 | 4.8 ± 0.55 |
| Week 6 (n=175, 176) | 8.0 ± 0.59 | 6.4 ± 0.60 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of \>41 for women and \>47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of ≤41 for women and ≤47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved.
| number of participants | Vortioxetine | Escitalopram |
|---|---|---|
| Week 1 (n=213, 205) | 48 | 36 |
| Week 2 (n=217, 206) | 81 | 63 |
| Week 4 (n=217, 206) | 93 | 84 |
| Week 6 (n=217, 206) | 112 | 93 |
| Week 8 (n=217, 206) | 113 | 91 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug (Up to 12 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | — | 3/224 (1.3%) | 90/224 (40.2%) |
| Escitalopram | — | 1/221 (0.5%) | 60/221 (27.1%) |
| Event | Vortioxetine | Escitalopram |
|---|---|---|
| DepressionPsychiatric disorders | 2/224 | 0/221 |
| Mesenteric vein thrombosisGastrointestinal disorders | 0/224 | 1/221 |
| Angina pectorisCardiac disorders | 1/224 | 0/221 |
| AnxietyPsychiatric disorders | 1/224 | 0/221 |
| NephrolithiasisRenal and urinary disorders | 1/224 | 0/221 |
| Event | Vortioxetine | Escitalopram |
|---|---|---|
| NauseaGastrointestinal disorders | 56/224 | 12/221 |
| HeadacheNervous system disorders | 21/224 | 17/221 |
| DizzinessNervous system disorders | 18/224 | 11/221 |
| IrritabilityGeneral disorders | 11/224 | 16/221 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 13/224 | 0/221 |
| FatigueGeneral disorders | 10/224 | 12/221 |
| AnxietyPsychiatric disorders | 4/224 | 12/221 |
All randomized set (N=447): All study participants who were screened and randomized to one of two treatment arms.
| Age, Continuous(years) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Mean | 39.3 ± 9.96 | 40.2 ± 10.01 | 39.8 ± 9.98 |
| Age, Customized(participants) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| ≤41 years | 122 | 112 | 234 |
| >41 years | 103 | 110 | 213 |
| Sex: Female, Male(Participants) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Female | 128 | 135 | 263 |
| Male | 97 | 87 | 184 |
| Race/Ethnicity, Customized(participants) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 36 | 50 |
| Non-Hispanic and Non-Latino | 211 | 186 | 397 |
| Race/Ethnicity, Customized(participants) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Caucasian (or White, including Hispanic) | 178 | 181 | 359 |
| Black of African American | 41 | 35 | 76 |
| Asian | 4 | 3 | 7 |
| American Indian or Alaska Native | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Region of Enrollment(participants) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| North America | 225 | 222 | 447 |
| Height(cm) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Mean | 169.6 ± 9.73 | 170.3 ± 8.81 | 169.9 ± 9.28 |
| Weight(kg) | Vortioxetine | Escitalopram | Total |
|---|---|---|---|
| Mean | 79.62 ± 16.202 | 81.22 ± 16.012 | 80.41 ± 16.110 |
8 further baseline measures are reported on the registry.
The record gives a start of Jun 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine
Sexual Dysfunction, Physiological →